Gene Editing Shop Recombinetics Surpasses $2M Fundraising Goal | GenomeWeb

NEW YORK (GenomeWeb News) – Gene editing firm Recombinetics today said that it surpassed its $2 million fundraising goal this month.

The St. Paul, Minn.-based firm did not disclose its investors.

Founded in 2008, Recombinetics is using a gene editing technology called TALENs to produce its first biomedical product and to develop the first agricultural products, it said on its website.

TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.